Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orvacabtagene autoleucel - Juno Therapeutics

Drug Profile

Orvacabtagene autoleucel - Juno Therapeutics

Alternative Names: Anti BCMA CAR T cell therapy - Juno Therapeutics; Anti-BCMA CAR - Juno Therapeutics; Anti-BMCA Chimeric antigen receptor cell therapy-Juno Therapeutics; BCMA-CAR-T-Juno Therapeutics; BCMA-specific CAR expressing T-Lymphocytes-Juno Therapeutics; BCMA-specific CAR-T-Juno Therapeutics; BCMA-Targeted CAR-T Cells-Juno Therapeutics; JCARH-125; orva-cel

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 04 Jun 2021 Updated efficacy and adverse events data from the phase I/II EVOLVE trial in Multiple myeloma presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 29 May 2020 Efficacy and adverse events data from the phase I/II EVOLVE trial in Multiple myeloma presented at 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 03 Dec 2018 Interim adverse events and efficacy data from phase I/II Evolve trial in Multiple myeloma presented at the 60th American Society of Hematology Annual Meeting (ASH-Hem-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top